Will G. Ryan, M.D.; Theodore B. Schwartz, M.D., F.A.C.P.; Charles P. Perlia, M.D.
This content is PDF only. Please click on the PDF icon to access.
Mithramycin, an antibiotic related to actinomyein D and used in the treatment of testicular cancer, has been noted to cause hypocalcemia during its administration. This observation and others led us to believe it might be active against Paget's disease. Treatment with this drug (25 µg/kg/day for 10 days) of two patients who had advanced Paget's disease of bone has apparently induced a prolonged beneficial effect. Studies during treatment revealed a change from negative to positive calcium and phosphate balance. Markedly elevated urinary hydroxyproline excretion (>800 mg/24 hr) was dramatically reduced to near-normal levels (50 mg/24 hr), and elevated isotopically determined
Learn more about subscription options.
Register Now for a free account.
Ryan WG, Schwartz TB, Perlia CP. Effects of Mithramycin on Paget's Disease of Bone.. Ann Intern Med. 1969;70:1103–1104. doi: 10.7326/0003-4819-70-5-1103_3
Download citation file:
Published: Ann Intern Med. 1969;70(5):1103-1104.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only